tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Alak AM and Lizak PP Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay. 1996 Ther Drug Monit pmid:8738766
Ockenfels HM et al. Inhibition of T cell cAMP formation by cyclosporin A and FK506. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8740144
Thompson PA and Mosley CA Tacrolimus-phenytoin interaction. 1996 Ann Pharmacother pmid:8740340
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Sheppard KE Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. 1995 J. Neuroendocrinol. pmid:8748119
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Miranker A and Karplus M An automated method for dynamic ligand design. 1995 Proteins pmid:8749844
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Ichinari H et al. Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. 1996 J. Thorac. Cardiovasc. Surg. pmid:8751494
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Ho SN et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996 Nature pmid:8752278
Motamedi H et al. Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520. 1996 J. Bacteriol. pmid:8752344
Yamashita M et al. Non-T cell-derived IL-4 plays an important role in IgE production induced by antigen resensitization and is resistant to FK506. 1996 J. Immunol. pmid:8752921
Sperr WR et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. 1996 J. Allergy Clin. Immunol. pmid:8757216
Venkataraman L et al. Differential regulation of c-Rel translocation in activated B and T cells. 1996 J. Immunol. pmid:8757620
Brunner T et al. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. 1996 Int. Immunol. pmid:8757947
Gusev AI et al. A quantitative study of in vitro hepatic metabolism of tacrolimus (FK506) using secondary ion and matrix-assisted laser desorption/ionization mass spectrometry. 1996 Rapid Commun. Mass Spectrom. pmid:8759330
Rokaw MD et al. FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. 1996 Am. J. Physiol. pmid:8760046
Tomono M et al. Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. 1996 Biochem. J. pmid:8760349
Becker G et al. Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. 1996 Transpl. Immunol. pmid:8762016
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Ichikawa Y et al. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. 1996 Int. J. Urol. pmid:8776613
Mugiya S et al. Renal blood flow and serotonin metabolism in tacrolimus treated rats. 1996 Int. J. Urol. pmid:8776615
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Singh N and Yu VL Prophylaxis for cytomegalovirus disease after liver transplant. 1996 Clin. Infect. Dis. pmid:8783744
Steiner JP et al. Immunophilin regulation of neurotransmitter release. 1996 Mol. Med. pmid:8784785
Silva ND and Prendergast FG Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. 1996 Biophys. J. pmid:8785272
Wagenknecht T et al. Cryoelectron microscopy resolves FK506-binding protein sites on the skeletal muscle ryanodine receptor. 1996 Biophys. J. pmid:8785329
Dumont FJ et al. Mixed agonist/antagonist activity of an FK-506-related immunosuppressant: biological and biochemical characterization. 1996 J. Pharmacol. Exp. Ther. pmid:8786538
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Gonschior AK et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. 1996 Clin. Chem. pmid:8787699
Venkataramanan R et al. Clinical pharmacokinetics of tacrolimus. 1995 Clin Pharmacokinet pmid:8787947
Ikebe S et al. Immunosuppressive effect of tacrolimus (FK-506). Bone xenografts in rabbits. 1996 Acta Orthop Scand pmid:8792745
Abu-Elmagd K et al. The current status of hepatic transplantation at the University of Pittsburgh. 1995 Clin Transpl pmid:8794262
Shapiro R et al. The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. 1995 Clin Transpl pmid:8794266
Buckle GJ et al. HTLV-I-induced T-cell activation. 1996 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:8797712
Platz KP et al. Management of acute steroid-resistant rejection after liver transplantation. 1996 World J Surg pmid:8798364
Brunke M et al. Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases. 1996 J. Biol. Chem. pmid:8798557
Zhang Q et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8799169
Spencer DM et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996 Curr. Biol. pmid:8805308
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Ho S et al. The mechanism of action of cyclosporin A and FK506. 1996 Clin. Immunol. Immunopathol. pmid:8811062
Nishino H et al. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. 1996 J. Chem. Neuroanat. pmid:8811425
Sonatore LM et al. The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains. 1996 Anal. Biochem. pmid:8811923
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Michel G et al. FK506 in the treatment of inflammatory skin disease: promises and perspectives. 1996 Immunol. Today pmid:8820265
Boeve BF et al. Dysarthria and apraxia of speech associated with FK-506 (tacrolimus). 1996 Mayo Clin. Proc. pmid:8820772
Komatsu K et al. Prolonged survival of hamster-to-rat pulmonary xenografts by tacrolimus (FK506) and cyclophosphamide. 1996 J. Heart Lung Transplant. pmid:8820789
Hodgkiss JP and Kelly JS Only 'de novo' long-term depression (LTD) in the rat hippocampus in vitro is blocked by the same low concentration of FK506 that blocks LTD in the visual cortex. 1995 Brain Res. pmid:8821755
Hayashi K et al. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats. 1996 Jpn. J. Pharmacol. pmid:8822088
Sasahara Y et al. Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification. 1996 J. Biol. Chem. pmid:8824230
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Matsuda H et al. Interactions of FK506 (tacrolimus) with clinically important drugs. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:8824931
Woodle ES et al. Treatment of acute glomerular rejection with FK 506. 1996 Clin Transplant pmid:8826664
Seifeldin R et al. Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus. 1996 May-Jun Clin Ther pmid:8829025
Moriwaki A et al. Immunosuppressant FK506 prevents mossy fiber sprouting induced by kindling stimulation. 1996 Neurosci. Res. pmid:8829156
Ankarcrona M et al. Calcineurin and mitochondrial function in glutamate-induced neuronal cell death. 1996 FEBS Lett. pmid:8830666
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Mysliwiec J et al. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats. 1996 Thromb. Res. pmid:8837316
Lamb GD and Stephenson DG Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. 1996 J. Physiol. (Lond.) pmid:8842013
Tanaka K et al. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. 1996 Pharm. Res. pmid:8842048
Borvak J et al. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. 1996 J. Infect. Dis. pmid:8843228
Borg AJ et al. 15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes. 1996 Transpl. Immunol. pmid:8843590
Chen BG et al. Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody. 1996 Transpl. Immunol. pmid:8843593
Toyota N et al. Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. 1996 Arch. Dermatol. Res. pmid:8844128
Stempfle HU [Osteoporosis following heart transplantation. Pathogenesis and therapy]. 1996 Dtsch. Med. Wochenschr. pmid:8846757
Akashi T et al. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. 1996 J Pharm Biomed Anal pmid:8851758
Wada Y et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. 1996 Artif Organs pmid:8853794
Lochmüller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. 1996 Gene Ther. pmid:8854096
Horn F and Gross J A role for calcineurin in Dictyostelium discoideum development. 1996 Differentiation pmid:8855370
Holt DW et al. Quality assessment issues of new immunosuppressive drugs and experimental experience. 1996 Ther Drug Monit pmid:8857551
McMichael J et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. 1996 Ther Drug Monit pmid:8857564
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849
Takuma T et al. Dephosphorylation of cofilin in parotid acinar cells. 1996 J. Biochem. pmid:8864841
Yamada A et al. Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. 1996 Microbiol. Immunol. pmid:8865157
Christians U et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. 1996 Br J Clin Pharmacol pmid:8866917
Dawson TM Immunosuppressants, immunophilins, and the nervous system. 1996 Ann. Neurol. pmid:8871573
Small SL et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) 1996 Ann. Neurol. pmid:8871576
Sadakane Y and Nakashima H Light-induced phase shifting of the circadian conidiation rhythm is inhibited by calmodulin antagonists in Neurospora crassa. 1996 J. Biol. Rhythms pmid:8872595
Jordan ML et al. The use of tacrolimus in renal transplantation. 1996 World J Urol pmid:8873438
Clark W Tacrolimus: immunosuppression following liver and kidney transplant. 1996 J Clin Pharm Ther pmid:8873845
DiMartini AF et al. Prospective study of FK506 side effects: anxiety or akathisia? 1996 Biol. Psychiatry pmid:8874843
Lu YF et al. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. 1996 Brain Res. pmid:8874888
Barkholt LM et al. Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents. 1996 Transpl. Int. pmid:8875785
Morris-Stiff G et al. Haemolytic uraemic syndrome associated with OKT3. 1996 Transpl. Int. pmid:8875800
Kitagawa H et al. Cloning and high expression of rabbit FKBP25 in cornea. 1996 Jpn. J. Ophthalmol. pmid:8876379
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381